gbola amusa md cfa head hc research
sale trade et
viral news genet medicin gm-base vaccin truce
relat news april april genet medicin gm vaccin program continu enter clinic
unrat dose subject dna vaccin phase trial enrol
healthi adult volunt initi data expect late summer oxford biomedica unrat
join consortium led oxford univers develop adenovir vaccin expect clinic
trial later month oncosec medic unrat provid st joseph healthar pursu
vaccin combin oncosec plasmid dna-encod version spike protein
unrat unrat disclos detail compani vaccin collabor see
arcturu therapeut buy announc plan initi mrna vaccin trial summer cansino
biolog unrat announc plan move vaccin phase ii trial soon base
preliminari safeti data phase trial propos intern random trial multipl
vaccin versu placebo group past week saw fewer announc trial disrupt gm space see
highlight week april april rna interfer rnai compani buy
buy announc collabor liver diseas cross-licens agreement
primari hyperoxaluria ph dicerna assum develop cost compani liver diseas
asset select product candid advanc dicerna us commerci right
alnylam option commerci outsid us addit alnylam dicerna also agre
non-exclus cross-licens compani respect intellectu properti ph highlight februari
februari research alnylam dicerna emerg leader rnai space believ
primari benefit agreement avoid futur litig diseas rel
major biopharma space us vivo gene therapi gt compani continu provid net posit updat
clinic program despit pandem gensight biolog buy announc limit impact
oper axov gene therapi buy announc remain track achiev key mileston
note near market bottom due under-perform space market disloc
advoc own vivo gt compani treatment compani less sensit trial disrupt
dose trial follow-up updat perform sinc februari stand sight ivgt
look forward april april april buy host virtual vaccin day includ
present ceo stphane bancel tal zak key opinion leader focus mrna vaccin well
compani core prophylact vaccin modal follow compani releas financi result johnson
weekli price move chardan genet medicin vivo gene therapi ex vivo gene therapi
price move sinc februari impact chardan genet medicin vivo gt ex vivo
upcom chardan genet medicin event contact chardan rsvp
gene express target set genet medicines-bas vaccin
pleas refer import disclosur inform regul analyst certif found page report
coalit epidem prepared innov cepi april publish natur review drug discoveri
current vaccin develop landscap author note april global landscap
includ vaccin candid current phase clinic trial includ genet medicines-bas vaccin
buy mrna unrat dna cansino biolog unrat adenovir
vector addit candid leverag variou dna rna engin viral vector platform expect enter
clinic come month develop unrat biontech/pf johnson johnson oxford biomedica
buy-rat arcturu other on-going pandem thu provid uniqu opportun benchmark next-gen
gm vaccin platform stack well tradit approach attenuated/
inactiv virus adjuv recombin protein safeti efficaci manufactur effici
platform advantag limit exampl dna rna vaccin rel simpl scalabl
manufactur need product live viru inde manufactur process dna rna
recombin viral vector vaccin remain differ viral target requir chang
genet sequenc antigen encod howev reactogen previous report
mrna vaccin dna vaccin requir special deliveri electropor achiev good
immunogen case adenovir vector vaccin individu may pre-exist immun develop
immun respons vector could creat challeng multi-dos regimen need
author natur review drug discoveri articl note may case vaccin platform may better
suit specif popul subtyp elderli children pregnant women immunocompromis patient
data precis need confer protect yet avail world organ
blueprint intern random trial target product profil publish april
togeth provid visibl key consider vaccin program outbreak set long-
term use exampl vaccin efficaci like measur term diseas rate compar vaccin
arm vs placebo though addit factor like viral shed transmiss could evalu well
look vaccin efficaci though would prefer outbreak set vaccin
elicit protect singl dose simpl syring administr and/or rapid immun onset week post-
dose would prefer would vaccin store higher temperatur facilit distribut term
safeti addit reactogen trial like evalu potenti enhanc diseas vaccin recipi
discuss februari research believ paramet like align vari extent
differ platform develop anticip demonstr flexibl scalabl set
posit genet medicines-bas platform broader use infecti diseas space
exicur announc timothi walbert succeed chad mirkin ph one compani founder
chairman board director believ transit much align exicur current stage growth
mr walbert skill set current chairman presid ceo unrat well-match
exicur guidanc need acceler number asset clinic
sight buy updat limit impact aav exposur april amusa
april gensight biolog announc limit impact far on-going pandem
concern recal march research advoc own basket vivo vector gene therapi
gt compani product treatment whose benefit measur futur visit even follow-up
visit miss also basket under-perform nbi sinc februari
take disclosur net posit given view lumevoq gate factor out-performance
scenario pandem concern prolong believ aav-bas devast diseas
 like zolgensma sma insul cautiou use steroid consid risk
infect long patient variou diseas still diagnos treatment window remain
open revenu product like lumevoq like delay elimin
buy updateon track achiev key mileston april amusa
april axov provid updat relat pandem confirm present axov
track achiev key mileston updat consist thesi establish march
vivo vector gt trial invest opportun on-going pandem concern
compani announc busi continu plan place protect safeti employe patient
mitig risk disrupt clinic program axov also track mileston
page
enrol continu plan ind clearanc expect year end
axo-lenti-pd phase ii sunrise-pd data track
genet medicin news april april
buy announc agreement buy rnai therapeut ph program april
announc collabor compani program
cross-licens agreement compani ph program
term agreement alnylam exercis option commerci outsid us parti
shall pay tier royalti parti base net product sale gener territori rate depend
candid commerci event alnylam waiv commerci option dicerna retain
world-wide right commerci select candid exchang mileston royalti payabl
alnylam also rate depend candid ultim commerci
ph agreement alnylam pay mid- high-single-digit royalti dicerna base global net sale
lumasiran dicerna pay low-single-digit royalti alnylam global net sale nedosiran
note alnylam lumasiran dicerna nedosiran differ mechan action potenti label
lumasiran target glycol oxidas potenti treatment ph type common form ph
nedosiran target lactat dehydrogenas potenti treatment ph type
unrat initi phase clinic trial vaccin dose patient april
evt gr unrat announc dedic site gene therapy-bas project april
evt gr unrat announc multi-year gene therapi research allianc unrat takeda april
mlm im unrat announc financi result provid busi updat april
onc unrat announc in-human trial dna-encod vaccin treat april
combi fn unrat announc posit preclin data focal epilepsi april
egenesi privat appoint david carmel svp public affair april
stanford publish method deliv surfac antigen tumor via oncolyt virus-en car-t april
univ washington publish method treat hemophilia use factor viii mrna lipid nanoparticl april
ut southwestern publish natur nanotechnolog method gene edit via lipid nanoparticl april
idra unrat announc privat placement million stock warrant april
buy complet roll nda submit lumasiran primari hyperoxaluria type april
unrat announc dose patient phase i/iia trial nhl cll sll april
unrat licens lentiboost technolog sirion biotech privat car-t pipelin april
enter non-exclus licens agreement sirion biotech access sirion
proprietari lentivir transduct enhanc lentiboost technolog util clinic develop
commerci beam portfolio car-t program
term agreement sirion receiv undisclos up-front mileston payment may receiv
royalti futur product net sale plu licens fee tie commerci success
citi center publish review stem cell-deriv aav gm applic april
emori univers publish lentivir gt famili hemophagocyt lymphohistiocytosi type april
univers minnesota publish gene edit system treat mp april
oxb ln unrat join univers oxford-l consortium develop vaccin april
quell privat announc collabor hannov school car-treg therapi april
unrat announc close mm collabor agreement unrat april
bntx unrat announc detail collabor unrat vaccin april
origin agre letter intent march co-develop distribut
exclud china mrna-bas vaccin
page
compani intend initi first clinic trial earli end april assum regulatori clearanc
us eu clinic develop stage partner provid clinic suppli
vaccin gmp-certifi mrna manufactur facil europ compani work togeth scale-
global manufactur capac commerci vaccin outsid china alreadi cover
biontech collabor fosun pharma unrat compani aim suppli million vaccin dose
end subject technic success develop program approv regulatori author
term agreement pay mm up-front includ mm cash
equiti invest mm furthermor elig receiv futur mileston payment
mm compani split develop cost equal fund percent cost initi
repay percent share cost vaccin commerci
arct buy announc clinic trial timelin vaccin dose expect summer april
announc propos intern random trial vaccin includ placebo april
buy file regulatori clearanc begin phase i/iia studi aro-enac cystic fibrosi april
compani mention report
page
select catalyst genet medicin coverag
nedosiran report multi-dos data phyox open-label trial primari hyperoxaluria
zolgensma anticip approv eu sma
xlrp end-of-phas ii meet fda xlrp
dose patient clear cell renal cell carcinoma
nedosiran complet enrol trial primari hyperoxaluria
report addit process data fanconi anemia
updat enrol cohort phase i/ii pioneer trial retin pigmentosa
submit ind diabet retinopathi
aro-enac file cta cystic fibrosi
present initi clinic data cardiovascular diseas
initi long-term follow-up initi patient phase i/ii studi batten diseas
b-vec initi pivot phase trial deb
report top-line interim result phase i/ii poc trial arci
nomin develop candid
initi phase ib studi liver kidney transplant recipi cscc
select lead product candid
complet assess cohort phase i/iia trial wet
suprachoroid initi phase ii trial wet use microinjector
suprachoroid submit ind phase ii trial dr use microinjector
report data secondari endpoint expand cohort phase i/ii hofh
zolgensma anticip approv japan sma
initi investigator-initi phase ii studi recurr glioblastoma
givosiran report addit result envison trial acut hepat porphyria
report phase data hypertriglyceridemia
report phase data dyslipidemia
aro-aat report biopsi data phase ii open label studi antitrypsin defici
report updat data phase i/ii trial pku announc expans cohort dose
provid updat guidanc phase i/ii trial initi time fda discuss
submit ind attr
report result phase ii nivolumab combin studi skin cancer cohort
provid interim data cohort phase i/ii trial mp ii
provid program updat preclin develop diseas
figur dicerna krystal expect import data read-out
page
select catalyst genet medicin coverag
report interim analysi phase ii trial cmv
report top-line result realiti observ natur histori studi lhon
submit ema lhon
report top-line result cohort phase i/ii pioneer trial retin pigmentosa
report multipl dose data chronic hepat infect
initi phase i/ii trial diabet retinopathi
present data phase optic studi wet
report data phase i/ii trial
xlrp report interim analysi group mo data group pi/ii trial xlrp
dose patient phase i/ii trial antitrypsin defici
report initi data phase i/ii studi batten diseas
b-vec initi clinic studi eu deb
initi dose patient clinic studi attr
report initi phase data danon diseas
report updat data phase i/ii trial lad-i
report preliminari phase data pyruv kinas defici
report preliminari phase ii data fanconi anemia
submit ind diseas
initi pivot trial subretin deliveri wet
suprachoroid initi phase ii trial dr use microinjector
suprachoroid interim data cohort wet w/ microinjector
program file ind oncology/inflammatori indic
lumasiran potenti fda/ema approv primari hyperoxaluria type
etranadez report top-line data pt pivot phase hope-b studi hem
zolgensma anticip approv switzerland canada australia sma
xlrp initi pivot phase trial xlrp
present initi proof concept data clear cell renal cell carcinoma
present stage data gangliosidosi
complet adult low mid-dos cohort
file ind sickl cell diseas
report result phase studi less ici respons tumor
report result phase ii nivolumab combin studi multipl solid tumor
report result monotherapi studi liver kidney transplant recipi cscc
report data nci trial combin checkpoint inhibitor gi cancer
initi piii studi hypertriglyceridemia
initi piii studi dyslipidemia
report addit data phase i/ii trial hemoglobinopathi
report initi data phase i/ii trial b-cell malign
submit ind file hemophilia
vy-aadc present result trial result trial pd
figur regenxbio replimun uniqur expect import data read-out
page
corpor report factset chardan note mention stock unrat unless state select public gm compani includ benitec biopharma
biomarin lysogen oxford biomedica neutral vbl buy
figur week end apr genet medicin vivo gt ex vivo gt ge srna mrna
page
week-over-week perform chardan genet medicin vivo gene therapi ex vivo gene therapi gene edit srna mrna basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap gene therapyvectortickerratingccm ptupsideclosechang changemc mm voyag gene therapiesaav genet n-f gene therapi exclud i/o vectortickerratingccm ptupsideclosechang changemc mm orchard editingtechnologytickerratingccm ptupsideclosechang changemc mm precis therapytechnologytickerratingccm ptupsideclosechang changemc mm arrowhead pharmaceut
corpor report factset chardan note mention stock unrat unless state select public gm compani includ benitec biopharma
biomarin lysogen oxford biomedica neutral vbl buy
figur apr vs feb genet medicin vivo gt ex vivo gt ge srna mrna
page
chardan genet medicin vivo gene therapi ex vivo gene therapi gene edit srna mrna basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap gene therapyvectortickerratingccm ptupsideclosechang changemc mm homolog medicinesaav n-f gene therapiesaav genet gene therapi exclud i/o vectortickerratingccm ptupsideclosechang changemc mm mustang editingtechnologytickerratingccm ptupsideclosechang changemc mm sangamo therapytechnologytickerratingccm ptupsideclosechang changemc mm pharmaceut
corpor report factset chardan note avx bold nite static market cap contribut post acquisit includ reflect valu creation within sector ise
ly pa oxb ln exclud due either modest size and/or histor non-vector-gt and/or ex vivo gt exposur confound analys vivo gt sector valuat
figur public genet medicin vivo gt ex vivo gt gene edit srna mrna therapi companiesend-monthli market cap select compani januari present
page
corpor report factset chardan note avx bold nite static market cap contribut post acquisit includ reflect valu creation within sector ise
ly pa oxb ln exclud due either modest size and/or histor non-vector-gt and/or ex vivo gt exposur confound analys vivo gt sector valuat
figur public vivo gene therapi companiesend-monthli market cap select compani januari present
page
figur public ex vivo gene therapi companiesend-monthli market cap select compani januari present
page
figur public gene edit companiesend-monthli market cap select compani januari present
page
corpor report factset chardan atrx bntc rgl sln ln exclud due modest size
figur public srna mrna therapi companiesend-monthli market cap select compani januari present
page
vivo gene therapi comp krystal meiragtx uniqur chardan top pick
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name ise model current market cap
refer partner product avexi novarti compani wet hofh mp mp ii phase i/ii trial
figur select public vivo gene therapi companiesw prefer buy buy buy qure buy greater potenti drive upsid space
page
targettargetccmpriceccmccmdiluteddil mcpercentccm ptshare mmof sector mmof sectorhighhighp shareshareof genet technolog gene therapiesaxgtbuyaav medicinesfixxbuyaav n-f pharmaceuticalsrcktbuyaav privat vivogt compani molecular akouo ask cardiac inhibitor estev freelin gener horama stride tamid taysha gene therapi tenaya vivet note marin lysogen ultragenyx addit unrat public compani genethon relev non-profit organ pharmaceut
gene edit comp see greater upsid potenti intellia
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name cll model current market cap
figur gene editingw broadli expect out-performance crispr gene edit sector higher potenti perform buy
page
targettargetccmpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof privat gene edit companiescarib scienc egenesi emendo therapeut excis mammoth scienc myogen poseida recombinet spotlight trucod gene repair verv technolog pharmaceut
srna mrna therapi comp alnylam top pick
corpor report factset chardan note mention stock unrat unless state target market cap unrat name bntx model current market cap
figur select public srna mrna therapi companiesw prefer buy buy greater potenti drive upsid entir srna mrna space
page
targettargetccmpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitalnylam privat srna mrna therapi companiesadvirna silense sirnaom somagen sylenti curevac ethri etherna immunotherapi genev scienc strand note adhera benitec pharma silenc addit unrat public compani pharmaceut
genet medicin therapeut approv posit opinion fda and/or ema
date
date
corpor report fda ema chardan note market author glybera expir due uniqur decis appli renew exclud antisens oligonucleotid figur
figur believ recent increas rate approv posit opinion genet medicin sign sector rapidli emerg
page
genet medicin therapeut receiv fda breakthrough therapi ema prime design
date fda btd
date ema prime
hattr amyloidosi polyneuropathi
corpor report fda ema biopharm insight chardan note ema start grant prime design may fda start grant breakthrough therapi design juli
figur believ disproportion amount btd prime design award genet medicin anoth sign sector rapidli emerg
page
date fda rmat
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur regen medicin advanc therapi design allow compani interact fda earlier clinic test process frequent
prioriti review voucher prv valu prv sold compani compani
date prv sale
swedish orphan biovitrum astrazeneca
ultragenyx undisclos
spark
ultragenyx novarti
biomarin undisclos
sarepta gilead
unit abbvi
sanofi
knight gilead
biomarin sanofi/regeneron pharmaceut
price prv
figur prioriti review voucher prv sold million million
page
date fda rpdd
ultragenyx genetx
retin pigmentosa exon mutat
corpor report fda biopharm insight chardan note list rpdd may incomplet sinc exampl compani disclos regulatori design
figur sinc pediatr diseas design potenti lead prioriti review voucher drug approv hidden sourc valu exist compani
page
date fda ftd
crispr vertex
crispr vertex
parkinson diseas mutat
rp due mutat exon gene
moder sever local scleroderma
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
date fda ftd
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
genet medicin select therapeut receiv btd rmat prime rpdd and/or ftd us eu
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genetx ultragenyx
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
parkinson diseas mutat
ftd grn mutat
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genet medicin regulatori design btd rmat prime ftd rpdd grant time
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design ema start grant prime design may
fda start grant breakthrough therapi design btd juli pediatr diseas design rpdd rmat design genet medicin began novemb
figur regulatori design btd rmat prime ftd rpdd grant genet medicin consider increas grant
page
designationsyear design grantedgenet medicin regulatori design ytd btdrmatprimeftdrpdd biotechnolog pharmaceut
